LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $112.60 Consensus Target Price from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $112.60.

A number of analysts recently commented on the company. Citizens Jmp increased their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Roth Mkm reaffirmed a “buy” rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Barrington Research increased their price target on LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 8,464 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 269,891 shares of company stock valued at $28,969,086. Insiders own 7.40% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. Sound Income Strategies LLC increased its position in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 183 shares during the last quarter. Cornerstone Planning Group LLC increased its position in LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares during the last quarter. Catalyst Capital Advisors LLC purchased a new stake in LeMaitre Vascular in the first quarter worth $32,000. MAI Capital Management purchased a new stake in LeMaitre Vascular in the third quarter worth $38,000. Finally, First Horizon Corp purchased a new stake in LeMaitre Vascular in the third quarter worth $39,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock opened at $97.75 on Monday. The company has a market cap of $2.23 billion, a PE ratio of 36.07, a price-to-earnings-growth ratio of 2.72 and a beta of 0.60. LeMaitre Vascular has a 52 week low of $78.35 and a 52 week high of $118.01. The business has a 50 day moving average price of $108.54 and a 200-day moving average price of $95.37. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts anticipate that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.90%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.